UK markets closed

Iovance Biotherapeutics, Inc. (0JDK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
22.78-0.72 (-3.06%)
At close: 4:09PM BST
Sign in to post a message.
  • J
    Joe
    In the words of IOVA's largest shareholder:

    “We believe that Iovance’s TILs will continue to be the most compelling therapy for solid tumors in the market and that Iovance has the most robust TIL data set,” the Cathie Wood-led firm said in a note to investors.

    “Furthermore, in our view, Iovance is trail-blazing the FDA regulatory process and likely will get FDA approval for its TIL therapy to treat melanoma, a very difficult-to-treat disease with high unmet need.”
  • J
    Jeffrey
    In response to drops like a rock in an upmarket
    You just need to know that the general market has nothing to do with iova
    What matters
    1 resolving the assay issue
    2 results of phase 2 and 3 trials

    If 1 &2 are positive the stock will fly so high your head won’t be able to take the altitude- So please stop talking about the market

    Early biotechs are dependent on the results of studies and general sentiment and how important the disease is they are trying to treat not how the market is doing .
  • J
    Jeffrey
    So now it’s even
    I wish they would stop listing pre market trades unless they are backed by significant news

    These single trades will make someone start drinking
  • G
    Glenn
    ARK has been selling IOVA the past couple of days. I guess they have given up. They are buying more FATE.
  • m
    ming
    Donot understand, very good data = sell off
  • J
    Jeffrey
    Iova May wind up becoming one the great companies fighting cancer and a seminal moment in changing the paradigm for cancer care but until they get the OK for assays you won’t see significant movement unless of course they are bought out
  • D
    Dan
    With these great results with a dingle dose ... why are they not doing trial cohorts with additional doses ? Seems like muti-dose could be a complete homerun
  • C
    ComedyClubster
    Guys, this will trade like BIIB -- yes, at $350+ -- when all the chips fall in place!!
  • G
    Glenn
    Ok, trying to find the positive. We are @ 68% off the low from May. I think if we get to $30 in July we are in a good position. Not trying to be unreasonably optimistic. But, get the CEO situation resolved, BLA/assay situation resolved or at least favorably communicated, and no other shoes dropping, maybe we are back in the 40’s by year-end. I know, “ nice dreams” have a good weekend.
  • j
    jsmith
    The longer they go without a CEO, the closer we are to a Buy Out. I'm happy.
  • u
    unser
    The 6 Best Robinhood Stocks To Buy Right Now - For more info https://youtu.be/niac0v4RFXs
    Now a penny may not get you a long way as a consumer, but so-called penny stocks offer investors the chance to bag a piece of small, but potentially lucrativ...
    Now a penny may not get you a long way as a consumer, but so-called penny stocks offer investors the chance to bag a piece of small, but potentially lucrativ...
    www.youtube.com
  • J
    Joe
    Two steps forward one back. See you at 30 soon. Data today was very good. Tutes using this opportunity to take shares from the uninformed.
  • A
    Andres
    The price action during market selloff tells you everything. Read the print. Soon the bird will sing!
  • V
    V
    is this going back up?
  • D
    DDD
    Should be back to 30s soon. Or higher given that the CEO that had a confrontational relationship with the FDA is gone and the positive data keeps rolling in.
  • H
    Hound
    The longer we go without a new CEO the more likely it is that the BOD is shopping the company around. Howwwllll!
  • B
    Brian
    going to touch $28 today
  • C
    ComedyClubster
    The avg. investor who trades on Cramer hype, msg board sentiment and an ignorance of the technology/science behind a company's product won't understand today's results. And it is that person that today's manipulated dive is hoping to get rid of. From the responses here I believe the MMs have been largely successful in their endeavour.
  • r
    rootbeerfloat
    Moving to a gap fill on the 1 month chart
  • j
    jsmith
    Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study

    Early Intervention with Lifileucel Following Progression on Anti-PD-1 Therapy May Maximize Benefit

    ASCO Update Conference Call and Webcast at 12 p.m. ET Today Anybody hear this call? Strange to have an announcement cement on Sunday, more strange to have a call?